---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022271"
form_type: "8-K"
ticker: "OCEA"
cik: "0001869974"
company_name: "Ocean Biomedical, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:01:13.520365+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ocean Biomedical faces Nasdaq delisting; CFO and director resign

## Summary
- Nasdaq Board declined to review Listing Council decision; final delisting action triggered under Rule 5830 and SEC Rule 12d2-2.
- Director Michael Petersen resigned effective August 31, 2025; no disagreement cited.
- CFO Jolie Kahn resigned effective August 5, 2025; no disagreement cited.
- Company continues to work on previously announced power and cryptocurrency strategies.

## SEC filing metadata
- accession: 0001641172-25-022271
- form_type: 8-K
- ticker: OCEA
- cik: 0001869974
- company_name: Ocean Biomedical, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869974/000164117225022271/0001641172-25-022271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869974/000164117225022271/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022271
- JSON: https://secwatch.observer/filing/0001641172-25-022271.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022271.txt

## Key facts
- Listing & Compliance Notices
  Ocean Biomedical, Inc. received a nasdaq delisting notice notice regarding other (rules 5820(e)(6), 5830).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5820(e)(6), 5830
  source text: July 31, 2025, the Company was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review the May 15, 2025 decision of the Nasdaq Listing and Hearing Review Council (the “Listing Council”) in the Company’s appeal proceding. Accordingly, pursuant to Nasdaq Rule 5820(e)(6), the decision of the Listing Council represents Nasdaq’s final action in this matter. Nasdaq will follow the procedures contained in Nasdaq Rule 5830 and the Securities and Exchange Commission (“SEC”) Rule 12d2-2 to remove the Company’s securities from listing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869974/000164117225022271/0001641172-25-022271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.